HALOZYME THERAPEUTICS, INC.
HALONasdaq
$77.81
↑ +0.3%Jul 17 close · end-of-day
Price
1Y↑ +34.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.6B
Enterprise Value
$11.4B
P/E
27.3
P/S
6.3
P/B
43.5
EV/EBITDA
21.7
PEG
1.3
FCF Yield
7.0%
Dividend Yield
—
Revenue (TTM)
$1.5B
Net Income (TTM)
$348.8M
Free Cash Flow (TTM)
$667.7M
Gross Margin
—
Operating Margin
33.9%
Net Margin
23.1%
ROE
158.8%
ROIC
17.3%
Debt / Equity
9.8
Net Cash
-$1.8B
Return 1Y
+34.6%
Company profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)
- CEO
- Helen I. Torley
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 390
- Headquarters
- California
- Website
- halozyme.com
Management & directors
- Torley HelenPRESIDENT AND CEO
- Ramsay David AEVP, PRESIDENT, DRUG DELIVERY
- Snyder Mark HowardSVP, CHIEF LEGAL OFFICER
- Caudill CortneySVP, CHIEF OPERATING OFFICER
- Labrosse NicoleSVP, CHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
HALO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$376.7M↑ +42.2%
Diluted EPS$1.22↑ +31.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $267.6M | $443.3M | $660.1M | $829.3M | $1.0B | $1.4B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $469.0M |
| Net income | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| Diluted EPS | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Operating cash flow | $55.5M | $299.4M | $240.1M | $388.6M | $479.1M | $651.6M |
| Free cash flow | $53.0M | $298.0M | $235.3M | $373.3M | $468.4M | $644.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Net margin | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $231.4M | $290.1M | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M | $376.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $117.2M | $163.2M | $175.5M | $141.5M | $202.4M | $217.9M | -$92.9M | $184.5M |
| Net income | $93.2M | $137.0M | $137.0M | $118.1M | $165.2M | $175.2M | -$141.6M | $150.0M |
| Diluted EPS | $0.72 | $1.05 | $1.06 | $0.93 | $1.33 | $1.43 | -$1.13 | $1.22 |
| Operating cash flow | $55.8M | $115.4M | $178.5M | $154.2M | $99.7M | $178.6M | $219.0M | $180.1M |
| Free cash flow | $53.2M | $113.9M | $175.4M | $153.3M | $98.1M | $175.6M | $217.6M | $176.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 50.7% | 56.3% | 58.9% | 53.4% | 62.2% | 61.5% | -20.6% | 49.0% |
| Net margin | 40.3% | 47.2% | 46.0% | 44.6% | 50.7% | 49.5% | -31.3% | 39.8% |
Company news
Jul 20, 2026
- 5h agoHalozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Developmentinvestorshub.advfn.com
- 8h agoHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technologyfinance.yahoo.com
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-08 | Torley Helen· PRESIDENT AND CEO | Sale | 1,035 | $80.19 | $82,993.55 | filing |
| 2026-07-08 | Torley Helen· PRESIDENT AND CEO | Sale | 888 | $79.28 | $70,397.09 | filing |
| 2026-07-08 | Torley Helen· PRESIDENT AND CEO | Option exercise | 1,923 | $12.07 | $23,210.61 | filing |
| 2026-07-01 | Connaughton Bernadette | Sale | 1,000 | $76.40 | $76,395.00 | filing |
| 2026-07-01 | Connaughton Bernadette | Sale | 625 | $77.21 | $48,255.63 | filing |
| 2026-06-30 | RAMSAY DAVID A· EVP, PRESIDENT, DRUG DELIVERY | Tax withholding | 5,408 | $78.27 | $423,284.16 | filing |
| 2026-06-30 | RAMSAY DAVID A· EVP, PRESIDENT, DRUG DELIVERY | Option exercise | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-29 | Krishnan Mahesh | Sale | 7,304 | $75.00 | $547,800.00 | filing |
| 2026-06-29 | Krishnan Mahesh | Option exercise | 7,304 | $38.46 | $280,911.84 | filing |
| 2026-06-12 | Snyder Mark Howard· SVP, CHIEF LEGAL OFFICER | Tax withholding | 2,715 | $69.50 | $188,692.50 | filing |
| 2026-06-12 | Snyder Mark Howard· SVP, CHIEF LEGAL OFFICER | Option exercise | 5,034 | $0.00 | $0.00 | filing |
| 2026-06-03 | Torley Helen· PRESIDENT AND CEO | Sale | 6,100 | $69.69 | $425,121.20 | filing |
| 2026-06-03 | Torley Helen· PRESIDENT AND CEO | Sale | 2,000 | $68.74 | $137,472.00 | filing |
| 2026-06-03 | Torley Helen· PRESIDENT AND CEO | Option exercise | 10,000 | $12.07 | $120,700.00 | filing |
| 2026-06-03 | Torley Helen· PRESIDENT AND CEO | Sale | 1,500 | $67.68 | $101,512.50 | filing |
| 2026-06-03 | Torley Helen· PRESIDENT AND CEO | Sale | 400 | $66.37 | $26,547.20 | filing |
| 2026-06-02 | Torley Helen· PRESIDENT AND CEO | Sale | 16,600 | $66.31 | $1.1M | filing |
| 2026-06-02 | Torley Helen· PRESIDENT AND CEO | Option exercise | 20,000 | $12.07 | $241,400.00 | filing |
| 2026-06-02 | Torley Helen· PRESIDENT AND CEO | Sale | 3,400 | $66.75 | $226,933.00 | filing |
| 2026-06-01 | Torley Helen· PRESIDENT AND CEO | Sale | 12,989 | $67.41 | $875,588.49 | filing |
| 2026-06-01 | Torley Helen· PRESIDENT AND CEO | Sale | 5,401 | $68.35 | $369,136.75 | filing |
| 2026-06-01 | Torley Helen· PRESIDENT AND CEO | Option exercise | 20,000 | $12.07 | $241,400.00 | filing |
| 2026-06-01 | Connaughton Bernadette | Sale | 1,625 | $66.21 | $107,591.25 | filing |
| 2026-06-01 | Torley Helen· PRESIDENT AND CEO | Sale | 1,610 | $66.39 | $106,884.68 | filing |
| 2026-05-13 | Torley Helen· PRESIDENT AND CEO | Sale | 3,950 | $69.79 | $275,658.65 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.